Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine

Abstract Background Malaria is a major global health challenge, and for the elimination and eradication of this disease, transmission-blocking vaccines (TBVs) are a priority. Plasmodium falciparum Generative Cell Specific 1 (PfGCS1), a promising TBV candidate, is essential for gamete fertilization....

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Zeinab Pourhashem, Leila Nourani, Jafar J. Sani, Hemn Yousefi, Sakineh Pirahmadi, Mobina Sabouri, Abbasali Raz, Navid Dinparast Djadid, Sedigheh Zakeri, Akram Abouie Mehrizi
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2023
Subjects:
Online Access:https://doi.org/10.1186/s12936-023-04798-7
https://doaj.org/article/e456798320eb40fdb50400042937b2e7
id ftdoajarticles:oai:doaj.org/article:e456798320eb40fdb50400042937b2e7
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:e456798320eb40fdb50400042937b2e7 2024-01-14T10:05:08+01:00 Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine Zeinab Pourhashem Leila Nourani Jafar J. Sani Hemn Yousefi Sakineh Pirahmadi Mobina Sabouri Abbasali Raz Navid Dinparast Djadid Sedigheh Zakeri Akram Abouie Mehrizi 2023-12-01T00:00:00Z https://doi.org/10.1186/s12936-023-04798-7 https://doaj.org/article/e456798320eb40fdb50400042937b2e7 EN eng BMC https://doi.org/10.1186/s12936-023-04798-7 https://doaj.org/toc/1475-2875 doi:10.1186/s12936-023-04798-7 1475-2875 https://doaj.org/article/e456798320eb40fdb50400042937b2e7 Malaria Journal, Vol 22, Iss 1, Pp 1-16 (2023) Malaria vaccine Cd-HAP antigen Adjuvants Immunogenicity SMFA Naturally acquired antibodies Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2023 ftdoajarticles https://doi.org/10.1186/s12936-023-04798-7 2023-12-17T01:48:06Z Abstract Background Malaria is a major global health challenge, and for the elimination and eradication of this disease, transmission-blocking vaccines (TBVs) are a priority. Plasmodium falciparum Generative Cell Specific 1 (PfGCS1), a promising TBV candidate, is essential for gamete fertilization. The HAP2-GCS1 domain of this antigen as well as its cd loop could induce antibodies that partially inhibit transmission of P. falciparum. Methods In the current study, a new synthetic fusion antigen containing cd loop and HAP2-GCS1 domain (cd-HAP) of PfGCS1 was evaluated as a transmission blocking vaccine candidate. Initially, the profile of naturally acquired IgG antibodies to the cd-HAP antigen was analysed in Iranian individuals infected with P. falciparum, to confirm that this new fusion protein has the appropriate structure containing common epitopes with the native form of PfGCS1. Then, the immunogenicity of cd-HAP was evaluated in BALB/c mice, using different adjuvant systems such as CpG, MPL, QS-21, and a combination of them (CMQ). Furthermore, the blocking efficacy of polyclonal antibodies induced against these formulations was also assessed by oocyst intensity and infection prevalence in the Standard Membrane Feeding Assay (SMFA). Results The naturally acquired antibodies (dominantly IgG1 and IgG3 subclasses) induced in P. falciparum-infected individuals could recognize the cd-HAP antigen which implies that the new fusion protein has a proper conformation that mimics the native structure of PfGCS1. Concerning the immunogenicity of cd-HAP antigen, the highest IgG levels and titers, by a Th1-type immune profile, and elevated antibody avidity were induced in mice immunized with the cd-HAP antigen formulated with a combination of adjuvants (P < 0.0001). Additionally, cytokine profiling of the immunized mice displayed that a high level of IFN-γ response, a Th1-type immune response, was produced by splenocytes from immunized mice that received cd-HAP antigen in combination with CMQ adjuvants (P < 0.0001). ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 22 1
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Malaria vaccine
Cd-HAP antigen
Adjuvants
Immunogenicity
SMFA
Naturally acquired antibodies
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
spellingShingle Malaria vaccine
Cd-HAP antigen
Adjuvants
Immunogenicity
SMFA
Naturally acquired antibodies
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Zeinab Pourhashem
Leila Nourani
Jafar J. Sani
Hemn Yousefi
Sakineh Pirahmadi
Mobina Sabouri
Abbasali Raz
Navid Dinparast Djadid
Sedigheh Zakeri
Akram Abouie Mehrizi
Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
topic_facet Malaria vaccine
Cd-HAP antigen
Adjuvants
Immunogenicity
SMFA
Naturally acquired antibodies
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
description Abstract Background Malaria is a major global health challenge, and for the elimination and eradication of this disease, transmission-blocking vaccines (TBVs) are a priority. Plasmodium falciparum Generative Cell Specific 1 (PfGCS1), a promising TBV candidate, is essential for gamete fertilization. The HAP2-GCS1 domain of this antigen as well as its cd loop could induce antibodies that partially inhibit transmission of P. falciparum. Methods In the current study, a new synthetic fusion antigen containing cd loop and HAP2-GCS1 domain (cd-HAP) of PfGCS1 was evaluated as a transmission blocking vaccine candidate. Initially, the profile of naturally acquired IgG antibodies to the cd-HAP antigen was analysed in Iranian individuals infected with P. falciparum, to confirm that this new fusion protein has the appropriate structure containing common epitopes with the native form of PfGCS1. Then, the immunogenicity of cd-HAP was evaluated in BALB/c mice, using different adjuvant systems such as CpG, MPL, QS-21, and a combination of them (CMQ). Furthermore, the blocking efficacy of polyclonal antibodies induced against these formulations was also assessed by oocyst intensity and infection prevalence in the Standard Membrane Feeding Assay (SMFA). Results The naturally acquired antibodies (dominantly IgG1 and IgG3 subclasses) induced in P. falciparum-infected individuals could recognize the cd-HAP antigen which implies that the new fusion protein has a proper conformation that mimics the native structure of PfGCS1. Concerning the immunogenicity of cd-HAP antigen, the highest IgG levels and titers, by a Th1-type immune profile, and elevated antibody avidity were induced in mice immunized with the cd-HAP antigen formulated with a combination of adjuvants (P < 0.0001). Additionally, cytokine profiling of the immunized mice displayed that a high level of IFN-γ response, a Th1-type immune response, was produced by splenocytes from immunized mice that received cd-HAP antigen in combination with CMQ adjuvants (P < 0.0001). ...
format Article in Journal/Newspaper
author Zeinab Pourhashem
Leila Nourani
Jafar J. Sani
Hemn Yousefi
Sakineh Pirahmadi
Mobina Sabouri
Abbasali Raz
Navid Dinparast Djadid
Sedigheh Zakeri
Akram Abouie Mehrizi
author_facet Zeinab Pourhashem
Leila Nourani
Jafar J. Sani
Hemn Yousefi
Sakineh Pirahmadi
Mobina Sabouri
Abbasali Raz
Navid Dinparast Djadid
Sedigheh Zakeri
Akram Abouie Mehrizi
author_sort Zeinab Pourhashem
title Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
title_short Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
title_full Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
title_fullStr Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
title_full_unstemmed Evaluation of a new fusion antigen, cd loop and HAP2-GCS1 domain (cd-HAP) of Plasmodium falciparum Generative Cell Specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
title_sort evaluation of a new fusion antigen, cd loop and hap2-gcs1 domain (cd-hap) of plasmodium falciparum generative cell specific 1 antigen formulated with various adjuvants, as a transmission blocking vaccine
publisher BMC
publishDate 2023
url https://doi.org/10.1186/s12936-023-04798-7
https://doaj.org/article/e456798320eb40fdb50400042937b2e7
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source Malaria Journal, Vol 22, Iss 1, Pp 1-16 (2023)
op_relation https://doi.org/10.1186/s12936-023-04798-7
https://doaj.org/toc/1475-2875
doi:10.1186/s12936-023-04798-7
1475-2875
https://doaj.org/article/e456798320eb40fdb50400042937b2e7
op_doi https://doi.org/10.1186/s12936-023-04798-7
container_title Malaria Journal
container_volume 22
container_issue 1
_version_ 1788059532494110720